VACUUM-ASSISTED EXCISION (VAE): A POTENTIALLY APPROACH FOR PERCUTANEOUS TREATMENT OF SMALL BREAST TUMORS

Abstract

Objective: The aim of this study was to evaluate vacuum-assisted excision (VAE) for percutaneous treatment of breast
cancers. Methods: This is a retrospective analysis of 1061 vacuum-assisted biopsies (VAB) and VAE for the diagnostic purpose of suspicious breast lesions in a breast unit between April 13, 2017 and November 28, 2020. In total, 116 cases with
complete data from VAB/VAE and surgical excision were evaluated. Excision following VAB/VAE was defined as complete
resection (CR) if there was no residual tumor, minimal residual disease (MRD) if residual tumor was ≤3 mm, gross residual disease (GRD) if residual tumor was ≥3 mm, and upgrade from DCIS on VAB/VAE to invasive cancer. CR and MRD
were combined as potentially resected and treated percutaneously (PRTP). The GRD and those with an upgrade to invasion were determined not suitable for percutaneous treatment. Results: The median age was 55.6 years (20–91; SD 12.27),
and the median tumor size on imaging was 11.6 mm (4–88; SD 10.59). Of the 116 tumors, 29 (25%) were CR, 18 (15.5%)
were MRD, 64 (55.2%) were GRD, and 5 (4.3%) were upgraded from DCIS to invasion. There were 47 (40.5%) tumors that
were PRTP, of which 10 (21.3%) were DCIS and 37 (78.7%) were invasive diseases (12 pure invasive carcinoma [IC], 24 IC +
DCIS, and 1 DCIS with microinvasion). In multivariate analysis, a VAE procedure (p=0.008, odds ratio [OR]: 4.4, 95%CI)
with low/intermediate nuclear grade (p=0.000, OR: 12.5, 95%CI) and final T≤10 mm (p=0.000, OR: 50.1, 95%CI) were associated with PRTP. In this retrospective analysis, the probability of PRTP of low/intermediate grade tumors smaller than
10 mm undergoing VAE was 84.58%. Conclusion: These data suggest that low/intermediate grade pT1a/b breast tumors
can be completely excised with percutaneous VAE. Based on this, small (≤10 mm) IC of low/intermediate grade could be
considered for entry to prospective randomized trials of VAE for local treatment, with a long-term follow-up to assess
recurrence rates. Standardization of the procedure should be recommended.